Capricor says HOPE-3 extension data show Deramiocel slows Duchenne upper-limb decline by 76% in delayed-start group
Bitget2026/10/05 13:08Capricor Therapeutics disclosed new 24-month HOPE-3 open-label extension data on deramiocel in Duchenne muscular dystrophy. Results were presented at the 2026 World Muscle Society Congress; a patient-focused webinar is set for Oct. 7, 2026. Patients who switched from placebo to deramiocel showed a marked slowdown in upper-limb functional decline versus their prior year. Two-year data in both study groups indicated slower deterioration than expected from untreated disease progression. Data were added to deramiocel’s BLA; FDA action is due by the Nov. 22, 2026 PDUFA target date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839308) on October 05, 2026, and is solely responsible for the information contained therein.
- Capricor Therapeutics disclosed new 24-month HOPE-3 open-label extension data on deramiocel in Duchenne muscular dystrophy.
- Results were presented at the 2026 World Muscle Society Congress; a patient-focused webinar is set for Oct. 7, 2026.
- Patients who switched from placebo to deramiocel showed a marked slowdown in upper-limb functional decline versus their prior year.
- Two-year data in both study groups indicated slower deterioration than expected from untreated disease progression.
- Data were added to deramiocel’s BLA; FDA action is due by the Nov. 22, 2026 PDUFA target date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
